drugset / Trial / NCT04410133

Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

NCT04410133

NaSingle-groupOpen-labelDiagnostic

Summary

An open-label, single dose, single arm, prospective, multicenter Phase 3 study to establish the diagnostic performance of 18F fluciclovine positron emission tomography (PET) in detecting recurrent brain metastases after radiation therapy

Timeline

Start
2020-10-26
Primary completion
2023-06-05
Completion
2023-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-fluciclovine Diagnostic / imaging agent 185 mbq Intravenous